The FDA approved 41 new therapeutics in 2014, but the bumper year fell short of the commercial power of the drugs approved in 2013.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
Signal Transduction and Targeted Therapy Open Access 23 September 2020
-
Changing R&D models in research-based pharmaceutical companies
Journal of Translational Medicine Open Access 27 April 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. 2014 FDA drug approvals. Nat Rev Drug Discov 14, 77–81 (2015). https://doi.org/10.1038/nrd4545
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4545
This article is cited by
-
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
Signal Transduction and Targeted Therapy (2020)
-
When will clinical trials finally reflect diversity?
Nature (2018)
-
Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53–MDM2 Interaction Useful in Targeted Cancer Therapy
Topics in Current Chemistry (2017)
-
High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model
Stem Cell Reviews and Reports (2017)
-
Changing R&D models in research-based pharmaceutical companies
Journal of Translational Medicine (2016)